SCHEDULE: Armistice Capital Discloses 3.99% Stake in Rigel Pharma
Beneficial Ownership Amendment
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a 3.99% beneficial ownership stake in Rigel Pharmaceuticals, Inc.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons,' have filed an Amendment No. 6 to Schedule 13G regarding their ownership in Rigel Pharmaceuticals, Inc.
- The filing indicates beneficial ownership of 724,000 shares of Rigel Pharmaceuticals' Common Stock.
- This ownership represents 3.99% of the class, based on 18,151,344 shares outstanding as of October 30, 2025.
- Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is also deemed to beneficially own the securities.
- The Reporting Persons hold shared voting and shared dispositive power over all 724,000 shares.
- The filing was made under Rule 13d-1(b), indicating a passive investment without the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently carry strong positive or negative sentiment. It is an amendment, but the document itself does not provide context on whether the ownership percentage has increased or decreased from previous filings.
Positives
- NA
Negatives
- NA
Risks
- The filing itself does not detail specific risks related to Rigel Pharmaceuticals, Inc. or its operations. It is a disclosure of beneficial ownership by an institutional investor.
Future Outlook
This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from Rigel Pharmaceuticals, Inc. or the reporting persons regarding the issuer's future performance.
Industry Context
This filing represents a routine disclosure by an institutional investor, Armistice Capital, LLC, and its managing member, Steven Boyd, regarding their passive stake in a pharmaceutical company. Such disclosures are common in the investment landscape and provide transparency into significant ownership positions, particularly for companies in the biotechnology and pharmaceutical sectors where institutional investment is prevalent.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake in the company, which can be a factor in assessing institutional confidence.
- Investment Professionals: Offers data points for tracking institutional ownership and potential shifts in investor sentiment, although this filing indicates a passive position.
Key Dates
| Date | Description |
|---|---|
| 2025-09-30 | Date of event which requires filing of this statement |
| 2025-10-30 | Date as of which 18,151,344 shares outstanding were reported on the Issuer's Form 10-Q |
| 2025-11-04 | Date the Issuer's Form 10-Q was filed with the SEC |
| 2025-11-14 | Date of filing of this Schedule 13G Amendment No. 6 |
Keywords
Rigel Pharmaceuticals, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.